PTCE Pharmacy Connect | Pharmacy Times

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence Educational Objectives Examine best practices for optimizing medication adherence and treatment initiation in hypercholesterolemia management Explain patient education and counseling for managing hypercholesteremia Faculty: Joseph Saseen, PharmD, BCPS, BCACP, CLS Professor and Associate Dean for Clinical Affairs University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Executive Director, Ambulatory Pharmacy Services Grady Health System Atlanta, Georgia Joseph Saseen, PharmD, BCPS, BCACP, CLS, has the following financial relationships with commercial interests to disclose: Other Support (Lipid Monitoring Committee): Amgen (VESALIUS and OCEAN(a))   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Novartis Consultant: Novartis, Regeneron   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-9999-25-069-H01-P. The activity is available for CE credit through March 31, 2026.   This activity is jointly provided by the University of Connecticut School of Pharmacy–Storrs and Pharmacy Times Continuing Education™, and is supported by an educational grant from Novartis Pharmaceuticals Corporation.   Please follow the link below to access this activity on PTCE and claim CE credit: www.pharmacytimes.org/hyperlipidemiapodcast

Educational Objectives Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence   Faculty Lauren Ledbetter, PharmD, BCOP Clinical Pharmacy Specialist, Thoracic Medical Oncology The James Cancer Hospital at The Ohio State University Columbus, Ohio   Moderator Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Clinical Pharmacy Manager University of Kansas Cancer Center Division of Hematologic Malignancies & Cellular Therapeutics   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-24-304-H01-P. The activity is available for CE credit through October 31, 2025.   This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.

Educational Objectives Review challenges that impact optimal treatment of skin barrier dysfunction in patients with acne who are seeking OTC care List strategies to individualize patient care and improve recommendations for patients with acne experiencing skin barrier dysfunction Faculty: Robin Laird Patient Advocate Los Angeles, California   Mary Barna Bridgeman, PharmD, BCPS, BCGP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey   Internal Medicine Pharmacist Robert Wood Johnson University Hospital-New Brunswick New Brunswick, New Jersey Mary Barna Bridgeman, PharmD, BCPS, BCGP, has no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose. An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.05 CEU) under the ACPE universal activity numbers 0290-0000-24-128-H01-P and 0290-0000-24-128-H01-T. The activity is available for CE credit through April 29, 2025. This activity is supported by educational grants from CeraVe and La Roche-Posay; L'Oreal USA, Inc.

Educational Objectives Recall the key characteristics of desmoid tumors (DT), including presentation, frequency, genetic mutations, development, and outlook for individual patients Outline practical solutions to improve managed care-driven communication with health care providers and address the clinical and financial burden of unresectable, recurrent DT Moderator: Laura Bobolts, PharmD, BCOP Senior Vice President of Clinical Strategy and Growth OncoHealth Plantation, Florida   Faculty: Christy Harris, PharmD, BCOP, FHOPA     Clinical Pharmacy Specialist                                                                Dana-Farber Cancer Institute Associate Professor Massachusetts College of Pharmacy and Health Sciences Boston, Massachusetts   Christy Harris, PharmD, BCOP, FHOPA and Laura Bobolts, PharmD, BCOP have no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-421-H01-P. The activity is available for CE credit through January 18, 2024. This activity is supported by an educational grant from SpringWorks Therapeutics.

To claim CE credit for this activity, please follow this link: www.pharmacytimes.org/atopic-derm-podcast-630 Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Educational Objectives Review patient barriers that impact optimal treatment of patients with atopic dermatitis (AD) who are seeking OTC care List strategies to individualize patient care and improve recommendations for AD Moderator: Mary Bridgeman, PharmD, BCPS, BCGP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey   Internal Medicine Clinical Pharmacist Robert Wood Johnson University Hospital New Brunswick, New Jersey   Faculty & Caregiver: Ashley Ellis, PharmD, MBA, CDECS ImPAcT Director & Assistant Professor The University of Tennessee Health Science Center Department of Clinical Pharmacy and Translation Science College of Pharmacy Memphis, Tennessee   Mary Bridgeman, PharmD, BCPS, BCGP has no financial relationships with commercial interests to disclose. Ashley Ellis, PharmD, MBA, CDECS, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Researcher AHRQ “Tennessee Heart Health Network” funding in form of salary release dollars Consultant: Global Parents for Eczema Research, Continuing Education Alliance, McGraw Hill   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-268-H01-P and 0290-0000-23-268-H01-T. The activity is available for CE credit through June 30, 2024. This activity is supported by an educational grant from CeraVe and La Roche-Posay. Brought to you in partnership with the National Eczema Association.

Educational Objectives Outline the place in therapy for targeted therapies based on patient-specific factors and subtype of early-stage breast cancer Recognize methods to improve patient treatment selection while mitigating toxicities in patients with early-stage breast cancer Faculty: Allison R. Butts, PharmD, BCOP Pharmacist Manager, Oncology Breast Oncology Clinical Pharmacy Specialist Acute Care Pharmacy Services UK HealthCare- Markey Cancer Lexington, Kentucky   Director, PGY2 Oncology Residency Program UK HealthCare Lexington, Kentucky Allison R. Butts, PharmD, BCOP, has the following financial relationships with commercial interests to disclose: Consultant: AstraZeneca; BeyondSpring (one-time advisory boards) Moderator: Laura R. Bobolts, PharmD, BCOP SVP, Clinical Strategy and Growth OncoHealth Laura R. Bobolts, PharmD, BCOP, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-239-H01-P. The activity is available for CE credit through May 31, 2024. This activity is supported by independent medical educational grants from AstraZeneca; Merck & Co., Inc.; Puma Biotechnology Inc., and Lilly.

Educational Objectives Recall the pathophysiology and clinical manifestations of Duchenne muscular dystrophy (DMD), as well as the burden of DMD and its impact on patient quality of life List the latest updates for the safety and efficacy data of new and approved disease-modifying therapies in the treatment of DMD   Faculty: Amanda Hickman, PharmD, MPH, MSCS Central Support Pharmacist – Neuro/Psych/Sleep Trellis Rx Atlanta, Georgia   Moderator: Jessica L. Kerr, PharmD, CDCES Associate Dean – Office Professional and Student Affairs Professor/Clinical Pharmacist Southern Illinois University Edwardsville School of Pharmacy Edwardsville, Illinois   Amanda Hickman, PharmD, MPH, MSCS, and Jessica L. Kerr, PharmD, CDCES, have no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-613-H01-P. The activity is available for CE credit through December 22, 2023.   This activity is supported by an educational grant from Sarepta Therapeutics.

Educational Objective: Outline various challenges and uncertainties affecting the optimization of treatment with novel immunotherapeutic modalities for relapsed/refractory diffuse large B-cell lymphoma.   Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist - Hematology University of Michigan Rogel Cancer Center Ann Arbor, Michigan   Moderator: Laura R. Bobolts, PharmD, BCOP SVP, Clinical Strategy and Growth OncoHealth Plantation, Florida   Victoria Nachar, PharmD, BCOP & Laura R. Bobolts, PharmD, BCOP, have no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-611-H01-P. The activity is available for CE credit through December 22, 2023.   This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc; Genmab; and AbbVie, Inc.

Educational Objectives Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP) Recall the efficacy and safety of emerging agents for the treatment of ITP   Moderator: Anthony J. Perissinotti, PharmD, BCOP To claim CE credit for this activity, please visit the link below: https://www.pharmacytimes.org/courses/advances-in-the-treatment-of-immune-thrombocytopenia-strategies-for-optimizing-clinical-and-patient-outcomes Hematology Clinical Pharmacist Specialist Clinical Team Leader Hematology/Oncology Adjunct Clinical Assistant Professor University of Michigan – Michigan Medicine Ann Arbor, Michigan   Faculty: Lisa Charneski, PharmD, BCPS Assistant Dean for Academic Affairs Philadelphia College of Pharmacy Associate Professor of Clinical Pharmacy Department of Pharmacy Practice Saint Joseph's University Philadelphia, Pennsylvania Anthony J. Perissinotti, PharmD, BCOP has the following relevant financial relationships with commercial interests to disclose: Consultant: AbbVie, BeiGene, Janssen Lisa Charneski, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEU) under the ACPE universal activity number 0290-0000-22-608-H01-P. The activity is available for CE credit through December 19, 2023.   This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.

The educational objectives are: • Review the pathophysiology of atopic dermatitis (AD) as well as the efficacy and safety data for topical JAK inhibitors that are approved and in development • Discuss the role of pharmacists as a part of the care team for patients with AD as well as the key counseling points and monitoring parameters   Faculty: Dennis Williams Moderator: Jamie McConaha

Educational Objectives Discuss the differing classes of B-cell maturation antigen-directed therapy for multiple myeloma Study the economic burden of multiple myeloma and cost-effective treatment strategies for B-cell maturation antigen-directed treatments Faculty: Joseph A. Kalis, PharmD, BCOP Ambulatory Oncology Pharmacist UCHealth Hematology/Oncology Colorado Springs, Colorado   Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA Director, Pharmacy Cancer Care Department of Pharmacy Mayo Clinic   Assistant Professor of Pharmacy Mayo Clinic College of Medicine and Sciences Rochester, Minnesota   Joseph A. Kalis, PharmD, BCOP, has the following financial relationships with commercial interests to disclose: Speakers Bureau: Oncopeptides, GSK Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following financial relationships with commercial interests to disclose: Grant/Research Support: AstraZeneza, Janssen Consultant: BeiGene Speakers Bureau: Pfizer   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-359-H01-P. The activity is available for CE credit through July 29, 2023.   This educational activity is supported by an educational grant from GlaxoSmithKline.

Introduction of moderator, faculty, and disclosures by Todd: ­We have an incredible discussion coming up with our moderator, Dr. Jessica Kerr, Professor and Clinical Pharmacy Specialist – Cardiometabolic at the Southern Illinois University Edwardsville School of Pharmacy in Illinois and Dr. Joanna Hudson, who is a tenured Professor in the Department of Clinical Pharmacy and Translational Science and the Department of Medicine (Division of Nephrology) at the University of Tennessee (UT) Health Science Center and a Clinical Pharmacist specializing in nephrology at Methodist Hospital in Memphis, TN. They will provide a brief overview of anemia in chronic kidney disease and highlight updates and advancements in the development of some of the emerging agents used.  If you haven't listened to the three other webinars in this learning series on anemia in chronic kidney disease, be sure to check them out at pharmacytimes.org. Outline updates and advancements in the development of HIF-PH inhibitors for anemia in chronic kidney disease.   Express the role of the pharmacist in managing anemia in CKD through early detection and coordination of care.    Guests:    Dr. Jessica Kerr PharmD Interim Associate Dean - Office of Professional and Student Affairs at Southern Illinois University Edwardsville   Dr. Joanna Hudson PharmD Professor at University of Tennessee Health Science Center Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of faculty and disclosures:  Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia. Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis   Educational Objective: Recognize the quality-of-life impacts and cost of therapy challenges patients with myelofibrosis face and explore strategies available to better manage this diagnosis.       Melissa Pozotrigo, PharmD, BCOP Senior Clinical Pharmacist OncoHealth Atlanta, Georgia   Melissa Pozotrigo, PharmD, BCOP, has no financial relationships with commercial interests to disclose.     Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-397-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objective: Outline the standard treatment options for myelofibrosis as well as review clinical data for Janus kinase inhibitors and emerging targeted therapies.     Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Hematology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan     Victoria Nachar, PharmD, BCOP, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-396-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objective: Review the etiology and pathophysiology of myelofibrosis, including the World Health Organization classification and diagnostic criteria.     Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Hematology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan   Victoria Nachar, PharmD, BCOP, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-381-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Accreditation and support statement: ·   PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. ·   This activity is supported by educational grant from GlaxoSmithKline. Objectives •   Review the guideline-recommended role of immune-based therapies in the management of endometrial cancer. •   Discuss access to care, cost of care and cost-effectiveness of Immune checkpoint inhibitors in the treatment of endometrial cancer.   Learn more about your ad choices. Visit megaphone.fm/adchoices

 Educational Objectives ·      Discuss currently available options for pre-exposure prophylaxis (PrEP) in the prevention of HIV. ·      Describe the role of pharmacists in improving PrEP uptake in the United States.      Faculty: Drew W. Cates, PharmD, AAHIVP, Educational Manager SynerGrx Chamblee, Georgia  Faculty, has the following financial relationships with commercial interests to disclose: Speaker's Bureau: Gilead   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.07 CEU) under the ACPE universal activity number 0290-0000-22-338-H02-P. The activity is available for CE credit through July 29, 2023. This activity is supported by an educational grant from ViiV. Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of faculty and disclosures:  Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia. Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  https://www.pharmacytimes.org/courses/multiple-myeloma-pharmacists-as-therapy-experts Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives • Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC) • Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations   Josiah D. Land, PharmD, BCOP Clinical Pharmacy Specialist – Thoracic Medical Oncology Department of Pharmacy Memorial Sloan Kettering Cancer Center New York, New York   Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose: Consultant (advisory board): Bristol Myers Squibb   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number0290-0000-22-388-H01-P. The activity is available for CE credit through July 29, 2023.   This activity is supported by educational funding provided by Amgen. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives ·      Review the efficacy and safety of emerging frontline immune checkpoint inhibitor (ICI) used as monotherapy and in combination regimens ·      Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient reported outcomes related with frontline use of ICIs in advanced NSCLC   Faculty: Paul Forsberg, PharmD, MHA, BCOP Director of Pharmacy Minnesota Oncology St. Paul, Minnesota   Latha Radhakrishnan, PharmD, BCOP Clinical Oncology Pharmacist The University of Illinois Hospital and Health Sciences System Clinical Assistant Professor University of Illinois at Chicago College of Pharmacy Chicago, Illinois   Paul Forsberg, PharmD, MHA, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Epizyme Speakers Bureau: AstraZeneca   Latha Radhakrishnan, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Taiho, Novartis, Exelixis Speakers Bureau: BMS, AstraZeneca, Taiho, Exelixis   Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta. Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-363-H01-P. The activity is available for CE credit through July 29, 2023.   This activity is supported by independent medical education grants from Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.  https://www.pharmacytimes.org/courses/continuing-the-conversation-optimizing-frontline-immunotherapy-outcomes-in-nsclc-and-managed-care-considerations Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of faculty and disclosures:  Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia. Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC https://www.pharmacytimes.org/courses/multiple-myeloma-recognizing-treatment-options Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives ·      Understand the impact of Janus kinase inhibitors for the management of atopic dermatitis (AD) ·      Examine key safety and efficacy data on new and emerging Janus kinase inhibitors utilized for the treatment of AD and select appropriate treatments Identify the role of the pharmacist in individualizing treatment for patients with AD through patient counseling and education Faculty: Svetlana Gerzenshtein, PharmD, BCPS, CSP Clinical Pharmacist Specialist Specialty Pharmacy Department University of Chicago Medical Center Chicago, Illinois Content Development Sarah Lant, PharmD Clinical Pharmacist Specialist UChicago Medicine Chicago, Illinois Svetlana Gerzenshtein, PharmD, BCPS, CSP, has no financial relationships with commercial interests to disclose. Sarah Lant, PharmD, has the following relevant financial relationship with a commercial interest to disclose: Other (faculty speaker training): Lily Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives ·      Recognize the role of biomarker expression in the selection of most appropriate treatment options for patients with endometrial cancer ·      Review strategies for identification and management of drug-related toxicities in patients receiving therapy with immune checkpoint inhibitors, targeted agents, or combination therapy    Faculty: Sarah Hayward, PharmD, BCOP Clinical Pharmacy Specialist, Gynecologic Oncology Stephenson Cancer Center at OU Health University of Oklahoma Health Science Center Oklahoma City, Oklahoma Sarah Hayward, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant (advisory board): GSK, Seagen/Genmab Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-322-H01-P. The activity is available for CE credit through June 30, 2023. This educational activity is supported by an educational grant from GlaxoSmithKline Learn more about your ad choices. Visit megaphone.fm/adchoices

This podcast will specifically focus on clinical safety and efficacy data supporting the use of new and emerging JAK inhibitors in the management of AD. Practical counseling points for pharmacists to provide individualized care and proper selection of therapy to patients with AD who are initiating therapy with JAK inhibitors will also be discussed. Faculty experts will review audience questions and identify best practices in the management of AD. o  The Role of JAK Inhibitors in the Management of Atopic Dermatitis: Latest Advances and Best Practices for the Pharmacist o  Introduction of faculty, affiliations, and disclosures We would like to thank Sarah Lant, PharmD for her contribution in developing the content for this podcast. Lana Gerzenshtein, PharmD and Sarah Lant have no relevant financial relationships with commercial interests to disclose. o  Accreditation and support statement PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by educational grants from Incyte. Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of faculty and disclosures:  Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida. Dr. Tobon has no relevant financial relationships with commercial interests to disclose. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of faculty and disclosures:  Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida. Dr. Tobon has no relevant financial relationships with commercial interests to disclose. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

 Lisa Dumkow, PharmD, BCIDP, Antimicrobial Stewardship Clinical Pharmacist, PGY-2 Infectious Diseases Pharmacy Residency Program Director, Mercy Health Saint Mary's, Grand Rapids, MI Lacy Worden, PharmD, PGY-2 Infectious Diseases Pharmacy resident, Mercy Health Saint Mary's, Grand Rapids MI [LP1]  Dr. Dumkow & Dr. Worden have no relevant financial relationships with commercial interests to disclose PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour of knowledge-based credit. This activity is supported by educational grants from GlaxoSmithKline.     The educational objectives for this activity are: o  Examine important milestones and recent updates in the treatment and management of COVID-19 o  Interpret safety and efficacy data for recently approved, authorized, or investigational agents for the treatment of COVID-19 o  Illustrate how pharmacists can assist with educating patients and other health care providers regarding the latest updates to the treatment of COVID-19 Summary statement of topic being discussed: This is a conversational interview which will focus on emerging therapies for the management of COVID-19 in the outpatient setting. A discussion around current and investigational therapies will be covered. Key takeaways and practical points will be the focus. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives Examine challenges in current treatment options for seizure clusters, including efficacy and safety, and differentiating routes of administration Highlight considerations in treatment of seizure clusters, including addressing barriers to treatment and providing patient counseling to improve outcomes Faculty: Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM  Professor Departments of Pharmacotherapy & Outcomes Science and Neurosurgery Virginia Commonwealth University, Medical College of Virginia Richmond, Virginia Neurocritical Care Clinical Pharmacist Virginia Commonwealth University Health Richmond, Virginia Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM, has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Department of Defense Consultant: UCB, Chiesi, Marinus, Alexion, Ceribell Speakers Bureau: UCB, Chiesi Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-129-H01-P. The activity is available for CE credit through March 31, 2023. This activity is supported by an educational grant from Neurelis Inc. Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FNCS, MCCM is Professor of Pharmacotherapy & Outcomes Sciences and Neurosurgery at Virginia Commonwealth University (VCU) School of Pharmacy, Medical College of Virginia Campus. She is a Past President of the Neurocritical Care Society. Dr. Brophy's research interests include neuropharmacotherapy, traumatic brain injury, biomarkers, hemostasis, stroke, and status epilepticus. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives Describe the impact of ADHD and new non-stimulant class of ADHD treatments Highlight the role of the pharmacist in patient counseling, monitoring and medication management in ADHD Faculty: Sandy Mullen, PharmD, BCPP Clinical Pharmacy Specialist - Child and Adolescent Psychiatry  Department of Pharmacy  Virginia Commonwealth University (VCU) Health Richmond, VA Sandy Mullen, PharmD, BCPP, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-127-H01-P. The activity is available for CE credit through March 30, 2023. This activity is supported by an educational grant from Supernus. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives • Review the clinical and economic burdens associated with transthyretin amyloidosis (ATTR) • Recall key characteristics supporting the use of current and emerging therapies for the treatment of ATTR including mechanisms of action, clinical data, dosing, administration, and potential adverse effects Faculty: Svetlana Goldman, PharmD, BCACP, CDCES Clinical Pharmacist UC Davis Health Sacramento, California Yvette Hellier, PharmD, BCACP Clinical Pharmacist UC Davis Health Sacramento, California The following contributors have no relevant financial relationships with commercial interests to disclose:  Faculty Svetlana Goldman, PharmD, BCACP, CDCES, and Yvette Hellier, PharmD, BCACP Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-045-H01-P. The activity is available for CE credit through February 28, 2023. This activity is supported by an educational grant from Alnylam Pharmaceuticals. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives Describe the impact of COVID-19 on surgical pain management  Review current postoperative pain management guidelines and emerging non-opioid treatment approaches for pain management, including safety and efficacy data on newer treatments, and key considerations for pharmacists Faculty: Jawad N. Saleh, PharmD, BS, BCPS, BCCCP Clinical Manager of Pharmacy Services Pharmacy Department The Hospital for Special Surgery New York, New York Faculty, has the following financial relationships with commercial interests to disclose: Jawad N. Saleh, PharmD, BS, BCPS, BCCCP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Heron Therapeutics, Baudax Bio Speakers Bureau: Heron Therapeutics, Baudax Bio Scientific Advisory Boards: Heron Therapeutics, Baudax Bio Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-046-H08-P. The activity is available for CE credit through February 24, 2023. This activity is supported by an educational grant from Heron. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives Discuss the role of disruptions in the gut microbiome in the development of Clostridioides difficile infection (CDI) and recurrent CDIs Review the efficacy, safety, and role of fecal microbiota transplantation and emerging microbiome-based drugs for treatment of CDIs and rCDIs Faculty: Kevin W. Garey, PharmD, MS Professor and Chair University of Houston College of Pharmacy  Houston, Texas Kevin W. Garey, PharmD, MS, has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Summit, Acurx, and Parakek Pharmaceuticals, and Seres Therapeutics Consultant: Ferring Pharmaceuticals Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-048-H01-P. The activity is available for CE credit through January 31, 2023. This activity is supported by a medical education grant from Ferring Pharmaceuticals. Participants can claim credit for this CE activity by following the link below: https://www.pharmacytimes.org/courses/the-promising-role-of-microbiome-based-drugs-for-the-treatment-and-prevention-of-recurrent-clostridioides-difficile Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objective Identify best practices for managing toxicities associated with therapies for the treatment of Waldenström macroglobulinemia   Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Ambulatory Hematology Oncology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan Faculty has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-457-H01-P. The activity is available for CE credit through June 20, 2022. This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives ·            Recognize best practices for managing adverse effects associated with immune checkpoint inhibitor (ICI)-targeted therapy combinations   Faculty: Jacob K. Kettle, PharmD, BCOP Pharmacy Manager Ellis Fischel Cancer Center Department of Pharmacy University of Missouri Health Care Columbia, Missouri   Faculty, has the following financial relationships with commercial interests to disclose: Jacob Kettle, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Speakers Bureau: Genentech, Merck, Amgen, Lilly, DSI Consultant: Pfizer, Lilly Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-21-438-H01-P. The activity is available for CE credit through December 17, 2022. This activity is supported by educational grants from Eisai Inc and Exelixis, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives ·             Describe the role of immune checkpoint inhibitor (ICI)-targeted therapy combinations across malignancies ·             Recall knowledge of ICI-targeted therapy combinations to treatment selection in patients with cancer   Faculty: Jacob K. Kettle, PharmD, BCOP Pharmacy Manager Ellis Fischel Cancer Center Department of Pharmacy University of Missouri Health Care Columbia, Missouri Faculty, has the following financial relationships with commercial interests to disclose: Jacob Kettle, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Speakers Bureau: Genentech, Merck, Amgen, Lilly, DSI Consultant: Pfizer, Lilly Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-21-437-H01-P. The activity is available for CE credit through December 17, 2022. This activity is supported by educational grants from Eisai Inc and Exelixis, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education™ (PTCE) provides industry-leading pharmacy CE to retail, oncology, managed care, specialty, and health-system pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Podcast 1: Waldenström Macroglobulinemia and Treatment Advancements with the Use of BTK Inhibitors Educational Objectives ·             Outline the pathophysiology of Waldenström macroglobulinemia (WM) and its connection to use of new and emerging drug therapies ·             Review clinical guidelines and treatment selection in patients with WM Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Ambulatory Hematology Oncology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan   Faculty has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-441-H01-P. The activity is available for CE credit through June 13, 2022.  This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Optimizing Care for People Living with HIV: Beyond Typical Risk Factors for Weight Gain | PTCE Connect Educational Objectives Describe recent data surrounding weight gain among people living with HIV (PLWH) who are on antiretroviral therapy Recognize the role of the pharmacist in the care of PLWH Continuing the Conversation – Individualizing the Management of HIV: A Focus on Weight Gain Introduction of faculty, affiliations, and disclosures Dr. David Koren, PharmD, MPH, BCPS, AAHIVP, Clinical Pharmacist Specialist in Infectious Diseases at the Temple University Health System, Philadelphia, Pennsylvania Dr. Koren has the following relevant financial relationships with commercial interests to disclose: Advisory Boards: Gilead, Thera, and ViiV Independent consulting: AbbVie and Thera Accreditation and support statement PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 credit hours of knowledge-based credit. This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. Access PTCE here: https://www.pharmacytimes.org/on-demand/continuing-the-conversation-individualizing-the-management-of-hiv-a-focus-on-weight-gain See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Educational Objectives: Discuss the various barriers to COVID-19 vaccine uptake including reasons for vaccine hesitancy Review how pharmacists can address the reluctance of COVID-19 vaccination in communities Faculty: Rachel Armstrong, PsyD Clinical Psychologist Portsmouth, NH Rachel Armstrong, PsyD, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-21-283-H06-P. The activity is available for CE credit through July 29, 2022. This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Adverse Effects versus Convenience of the COVID-19 Viral-Vector Vaccines Educational Objectives: Articulate the benefits of viral-vector vaccines compared with the risk of thrombosis with thrombocytopenia syndrome (TTS) Elaborate on current viral-vector TTS adverse effect incidence data and risk among patients who have received or will receive a viral-vector vaccine  Faculty: James Lewis, PharmD, FIDSA ID Clinical Pharmacy Supervisor Oregon Health & Sciences University Portland, Oregon James Lewis, PharmD, FIDSA, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-21-264-H06-P. The activity is available for CE credit through June 29, 2022. This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Implementing Digital Technology Tools within Health-Systems for Improving Adherence and Patient Support Educational Objectives: At the completion of this activity, participants will be able to: Define the pharmacist's role in implementing digital and telemedicine technologies within the health system to improve adherence and provide remote patient monitoring and management. Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan He has no relevant financial relationships with commercial interests to disclose. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of knowledge-based credit. Click here to view the activity on the PTCE website and claim your credit: https://www.pharmacytimes.org/on-demand/bcell-malignancies-podcast-part2 This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene. See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Foundations of Evidence for the Use of BTK Inhibitors in B-Cell Malignancies and Management Strategies for Cardiac and Bleeding Adverse Effects Educational Objectives: At the completion of this activity, participants will be able to: Outline the efficacy of oral BTK inhibitors across B-cell malignancies including a focus on emerging clinical data Recognize pharmacists' responsibilities for monitoring and managing cardiac adverse effects specific to different health-system practice types Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan He has no relevant financial relationships with commercial interests to disclose. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of knowledge-based credit. Click here to view the activity on the PTCE website and claim your credit: https://www.pharmacytimes.org/on-demand/bcell-malignancies-podcast-part1 This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene. See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices